ARTICLE | Top Story
LLS launches collaborative AML trial
October 18, 2016 7:00 AM UTC
On Tuesday, the Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia.
The trial will enroll newly diagnosed AML patients aged 60 or older. Patients will be screened using a genomic profiling assay from Foundation Medicine Inc. (NASDAQ:FMI) for hematologic malignancies. Patients will then be assigned to one of four treatment arms based on their genetic profiles. ...